Biogen Builds Out Parkinson's Pipeline With Denali Deal
Executive Summary
Biogen will pay Denali $560m up front plus a $465m equity investment in exchange for co-development and co-commercialization rights to clinical-stage LRRK2 inhibitors for Parkinson's disease.
You may also be interested in...
Flagship's $3.37bn Fund To Grow First-In-Category Firms
Flagship, the investor behind COVID-19 success story Moderna, has raised a huge fund that will be used to create and develop its own companies before spinning them off.
Biogen Bets Big To Bag Sage Depression And Tremor Drugs
Rather than hitting the acquisition trail, Biogen has taken the licensing route to expand its psychiatric and neurological disorders pipeline.
Dealmaking Quarterly Statistics, Q3 2020
During Q3 biopharmas reached $41.7bn in merger and acquisition value and drew in $44.4bn in potential deal value from alliances. Device company M&A values reached $17.9bn while in vitro diagnostic firms and research tools players completed M&A activity that totaled $8.2bn.